Impact of adjuvant trastuzumab treatment on fatigue, emotional status and quality of personal and work life of patients with localised breast cancer: results of the ‘HER-ception’ study-Reference-Cited by-同舟云学术

Impact of adjuvant trastuzumab treatment on fatigue, emotional status and quality of personal and work life of patients with localised breast cancer: results of the ‘HER-ception’ study

Published:2022-12-16 Issue:1 Volume:31 Page:
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Le Gall Gwenn,Noal Sabine,Heutte Natacha,Clarisse Bénédicte,Leconte Alexandra,Cherifi François,Delcambre Corinne,Joly Florence,Clin Bénédicte

Funder

French Ligue Contre le Cancer

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-022-07512-6.pdf

Reference31 articles.

1. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 30(8):1194–1220

2. Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D et al (2019) Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol 20(3):361–370

3. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the herceptin adjuvant (HERA) trial. Lancet Lond Engl 389(10075):1195–1205

4. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol Off J Eur Soc Med Oncol 24(9):2278–2284

5. Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M et al (2018) Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol Off J Eur Soc Med Oncol 29(3):646–653